Logo

Progenity: Adi Mohanty

Nov 10, 2021

Adi Mohanty has been appointed as CEO of Progenity. He is also joining the firm's board of directors. Previously, he was the CEO of BioTime, and before that, a VP at Transkaryotic Therapies. Following the acquisition of Transkaryotic by Shire, he held several executive positions at Shire, including president of regenerative medicine. Mohanty holds an MS in chemical engineering from Clarkson University and an MBA from Saint Mary's College, California.

Breaking News
The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.